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Cancer has become the top killer of Man in recent decades. Thus, effective cancer 
detection is crucial as cancer can be easily tackled at its early stages. Molecular 
imaging enables the detection of a disease in its earliest stage. Three medical imaging 
techniques often used in the current clinical practice are the X-ray computed 
tomography (CT), positron emission tomography (PET) and magnetic resonance 
imagery (MRI). CT and PET scans involve radiation exposures. Hence, the non-
invasive MRI is preferred. 
To provide a better contrast in MRI, contrast agents are introduced. 
Superparamagnetic iron oxide (IO) is widely used as a contrast agent for MRI. It 
exhibits excellent magnetic properties and acceptable biocompatibility. IO can vastly 
enhance imaging due to its exceptional penetration depth. Furthermore, it has zero 
retained magnetism after the removal of magnetic field. Another probe used for 
amplification strategy is quantum dots (QDs) as luminescence probes in fluorescence 
imaging. Advantages of fluorescence imaging includes high sensitive detection, 
multicolor detection, probe stability, low hazard and low cost. Contrast agents such as 
organic fluorescent dyes and Quantum Dots (QDs) are often used to promote 
fluorescence imaging. Quantum dots (QDs) are composed of atoms from groups II-VI 
or III-V of the periodic table. Their advantages include in vivo longevity and tunable 
emission from visible to infrared wavelength by changing the size and composition of 
QDs. QDs also have broad excitation spectra with high absorption coefficients, high 
quantum yield of fluorescence, strong brightness, high resistance to photobleaching 
and good sensitivity.  
Although necessary, amplification strategies are not enough to produce high quality 
images. Sufficient concentrations of probes must be gathered at the intended imaging 
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area for an adequate period in vivo. Nevertheless, the agent dose is limited by the side 
effects of the agent and the rapid removal of probes from the blood system due to the 
body’s mononuclear phagocyte system (MPS) interactions after opsonization. A 
method to cloak nanoparticles from MPS recognition is the surface modification of 
the probes to prevent opsonin proteins in the blood from being attached to the 
particles surfaces. Generally, hydrophilic particles opsonize slower than hydrophobic 
particles and neutrally charged particles opsonize slower than charged particles. Till 
date, the most effective and most commonly used polymers as shielding groups are 
the PEG-containing copolymers. One important example of such a copolymer is poly 
(lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) 
that is gaining popularity in the research scene today. 
Certain probes may have very good affinity with certain targets of imaging interest 
however they may pose to be toxic to the body. To use such probes, encapsulation via 
PEGylation may be needed to reduce cytotoxicity. Another method to decrease 
cytotoxicity is by targeted delivery. Targeting is divided into passive and active 
targeting. In passive targeting, nanoparticles accumulate at the tumor through the 
enhanced permeability and retention (EPR) effect. The vascular structures of tumors 
are defective and lack effective lymphatic drainage system, causing particles to 
accumulate in them. Passive targeting is the prime objective for our probe system to 
achieve. 
Molecular imaging requires high affinity probes with reasonable pharmacodynamics. 
Such probes are usually nanoparticles. Synthesizing imaging probes into 
nanoparticles not only aids in escaping MPS detection but also increases cellular 
uptake. Thus, the formulation of imaging probes such as IOs and QDs in 
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nanoparticles of biodegradable polymers may provide an ideal solution to reduce 
toxicity as well as enhance cellular uptake, hence improving imaging effects. 
IO and QD probes are effective probes for amplification in molecular imaging. 
However, individual imaging probes have their advantages and disadvantages. For 
instance, IO probes provide high spatial resolution and unlimited depth penetration 
but their sensitivity in imaging fails in comparison to optical fluorescence imaging 
probes such as QDs. QDs, in turn; have excellent imaging effects and long half-life, 
but their ability for tissue penetration is limited due to the refraction and adsorption of 
light in the living organism. Therefore, it is very important to find an imaging method 
that can fulfill the requirements in medical applications as much as possible, and this 
can be achieved by applying multi-modal imaging.  
Multi-modal imaging means applying two or more imaging modalities concurrently. 
Multimodal imaging can be developed to make use of the advantages and overcome 
the limitations, which can be realized by co-encapsulation of QDs and IOs in ligand-
conjugated nanoparticles of biodegradable polymers. To achieve a thorough analysis 
of one multi-modal imaging system, in vivo, ex vivo and in vitro analyses should be 
done and cross-referenced. Most studies in the research field are related to either ex 
vivo or in vitro analysis, lacking in in vivo analysis. In addition, some imaging 
modalities such as CT imaging have significant side effects on human health. Both 
fluorescence imaging and MRI will not cause radiation injury. On top of that, QDs 
and IO as contrast agents have been widely studied in biomedical applications. 
Therefore, encapsulating both QDs and IO in PLA-TPGS copolymers, as multi-modal 
imaging probes should provide high quality images. This probe should have high 
sensitivity and depth penetration. 
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This thesis illustrates a multimodal imaging system developed by co-encapsulating 
superparamagnetic iron oxides (IOs) and quantum dots (QDs) in the nanoparticles 
(NPs) of poly (lactic acid) - d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-
TPGS) for use in both magnetic resonance imaging (MRI) and fluorescence imaging. 
This multimodal imaging system not only combines the advantages of both MRI and 
fluorescence imaging, but also overcomes their disadvantages. This imaging system 
also promotes sustained and controlled imaging with passive targeting effects to the 
diseased cells. The QDs and IOs-loaded PLA-TPGS NPs were prepared by a modified 
nanoprecipitation method, which were then characterized for their size and size 
distribution, zeta-potential and the imaging agent encapsulation efficiency. The 
transmission electron microscopy (TEM) images showed direct evidence for the well-
dispersed distribution of the QDs and IOs within the PLA-TPGS NPs. The cellular 
uptake and the cytotoxicity of the PLA-TPGS NPs formulation of QDs and IOs were 
investigated in vitro with MCF-7 breast cancer cells, which were conducted in close 
comparison with the free QDs and IOs at the same agent dose. To investigate the 
biodistribution of the QDs and IOs-loaded PLA-TPGS NPs among the various organs, 
animal studies were conducted where mice cultivated with MCF-7 breast cancer 
tumors were injected with the developed NPs. The results showed greatly enhanced 
tumor imaging due to the passively targeting effects of the NPs to the tumor. Images 
of tumors were acquired in vivo by a 7T MRI scanner. Further ex vivo images of the 
tumors were obtained via confocal laser scanning microscopy. Such a multimodal 
imaging system shows great advantages of both contrast agents making the resultant 
probe highly sensitive with good depth penetration. A subject administered with the 
developed NPs can undergo both MRI and fluorescence imaging. Any imagery 
feature detected in one imaging picture which may suggest any disease or tumor 
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growth, can be further compared and confirmed with the imaging picture taken by the 
other imaging technique.  
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Cancer is the result of the uncontrolled growth and spreading of abnormal cells (Feng 
SS and Chien S, 2003). Cancer cells can spread in the body through the blood and 
lymph systems (http://www.cancer.gov/cancertopics/what-is-cancer). Cancer is the 
leading cause of death in various developed countries. In the United States, there were 
about 1,529,560 new cases of cancers reported in 2010. On top of that, cancer 
associated death cases amounted to an alarming 569,490 in the very year 
(http://www.cancer.gov/cancertopics/what-is-cancer). Therefore, it is evidently 
important to find efficient ways to combat cancer. 
Massive advancements have actually been made in cancer treatments as compared to 
the last decade. However, developments in molecular imaging systems to detect 
cancer witnessed rather sluggish progress. Molecular imaging is an in vivo 
characterization and measurement of the disease process at the cellular and molecular 
level, which aims at investigating cellular functions without disturbance. In actual 
fact, in order to effectively overcome cancer, it is of paramount importance to first 
efficiently detect them. This is because, just like any other diseases, cancers can be 
easily and effectively treated in their early stages especially before tumors 
metastasize. Developing an advanced imaging system to detect cancer can realize this. 
In recent years, researchers have finally realized the importance of advancing imaging 
techniques resulting in great interests in advanced cancer imaging systems. Scientists 
expected that by using efficient cancer imaging techniques, the stage and precise 
locations of cancer could be determined efficiently. Apart from that, cancer imaging 
can also aid cancer treatment especially during operations and help monitor the 
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treatment effects (http://imaging.cancer.gov/imaginginformation/cancerimaging). 
Thus, an effective cancer imaging system is highly in demand.  
In order to enhance molecular imaging, contrast agents are utilized as imaging probes. 
Contrast agents make molecular imaging possible and effective by enhancing the 
image contrast between healthy and abnormal tissues. Thus, they are needed for many 
imaging techniques. However, most contrast agents have some toxicity issues and are 
thus not biocompatible. Besides causing some sides effects in the human body due to 
the toxicity, some contrast agents may have cell uptake limitation and could not be 
efficiently delivered into cells. On top of that, human immune system detection of 
these foreign contrast agents may also cause circulation limitations. Therefore, it is 
crucial to find a better way to control deliver the contrast agents into human cells 
while decreasing their cytotoxicity. Researchers found that by modifying contrast 
agents into nanoparticles, advantages such as the desired control delivery system, long 
vascular half-life and fewer side effects on human body can be achieved. In doing so, 
the imaging quality can be increased and it will be easier for doctors to find the 
accurate position of cancer in the body, locate the extent of cancer spreading, identify 
specified cancer treatment and monitor the effect of the treatment. 
Although contrast agents could enhance molecular imaging, every individual contrast 
agents have its advantages and limitations. Therefore, by only using one contrast 
agent and utilizing one mode of imaging may result in certain features within organs 
suggesting the onset of a particular disease to be overlooked. Therefore, the idea of 
dual modality was born which involves combining two contrast agents into a single 
probe. One dosage of this probe enables the patient to undergo two modes of imaging 
techniques. The results of the imaging can then be analyzed concurrently. This acts as 
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a more effective imaging practice to ensure no diseases get overlooked and left to 
develop into tricky late stages where treatment may be complicated.  
 
1.2 Objectives and Scope 
 
The main objective of this project is to encapsulate both quantum dots (QDs) and 
superparamagnetic iron oxide (IO) in biodegradable copolymer PLA-TPGS. Basic 
characterization studies will be conducted on the nanoparticles to investigate the 
particle size, polydispersity, surface charge and encapsulation efficiency. Cell line 
work will be conducted using the nanoparticles. Cell studies include cell uptake and 
cell toxicity experiments. On top of that, bio distribution experiments will be 
conducted on treated cancer induced animals. Finally, molecular imaging will also be 




CHAPTER 2: LITERATURE REVIEW 
  
2.1 Cancer Facts 
Cancer is currently the leading cause of death globally. According to the US National 
Cancer Institute, cancer is defined as a category of affiliated diseases whereby 
abnormal cells go through uncontrolled transformation (or mitosis) and have the 
ability to spread to other parts of the body via the blood circulation and lymphatic 
systems (metastasis).  
In the normal state, cells grow and replicate to form new cells according to the needs 
of the body. Whenever cells grow old and die, new cells replace them. However at 
times, this ideal orderly process goes wrong in which new cells form when the body 
does not need them, and old cells do not die when they should. The resultant extra 
cells gather to form a mass of tissue. This mass is known as a tumor. Tumors can be 
either benign (non cancerous) or malignant (cancerous). Benign tumors are localized 
and do not spread to other parts of the body. They are rarely life threatening. 
Malignant tumors, on the other hand, can spread (metastasize) and may be life 
threatening (http://www.cancer.gov/cancertopics/what-is-cancer).  
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Figure 2.1: Cancer formation through mutations. 
(Adapted from http://www.chemcases.com/cisplat/cisplat19.htm) 
 
A projection from statistics revealed that for every three people, one would be 
diagnosed with cancer in his lifetime. On top of that, occurrences rate of cancer are 
increasing at a rate of 1% per year (http://news.bbc.co.uk/2/hi/health/3444635.stm). 
Till today, more than 200 different types of cancer have been discovered. The 
probability of getting cancer is distinct in different types of tissues or organs, even 
within the same individual.  
2.2 Causes of Cancer  
There are various causes for cancer. These causes can basically be subdivided into 
two categories, namely the intrinsic and extrinsic factors. Intrinsic factors mainly 
include the genetic make up of the body and the individuals cannot control this. It 
implies that once a person is born, the genetic make up has already been coded to 
determine the number of genetic mutations he or she will experience in the lifetime. 
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Some of these mutations may ultimately lead to cancer. The causes of such mutations 
include inheritance from previous generations, abnormal fertilization or improper 
fetal developments during pregnancy. Mutations may not always result in cancer. 
However, inheritance of certain harmful gene mutations may increase the risk of 
cancer development. For instance, research has shown that women who inherited 
harmful BRCA1 and BRCA2 gene mutations can have a very higher risk of 
developing breast cancer in their lifetime as compared to those who did not inherit 
such gene mutations (http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA).  
In general, extrinsic factors play a bigger role in determining the development of 
cancer. Extrinsic factors encompass a wide variety of causes, ranging from 
environmental factors to the individual’s personal daily lifestyle. Daily lifestyle 
practices such as diet directly influences the risk of getting cancer. Preservatives such 
as nitrosamine, nitrosamide, sulphites as well as colorings, which are usually added 
during food processing, can potentially accumulate in the body over an extended 
period of time and cause cancer (http://www.cfsan.fda.gov/~dms/fdpreser.html; 
http://www.nswcc.org.au/editorial.asp?pageid=2345). Genetically-modified food 
(staples such as rice and potatoes included) as well as food rich in methyl donors has 
been reported to be able to potentially trigger genetic mutations, stimulating tumor 
growth (Watters, 2006; http://www.independent.co.uk/life-style/health-and-
wellbeing/health-news/suppressed-report-shows-cancer-link-to-gm-potatoes-
436673.html). Besides dietary habits, harmful habits such as smoking and drinking 
are also major factors causing cancers. For instance, more than 38,000 people are 
diagnosed with lung cancer every year. Of these deaths, almost 90% is tobacco related 
(http://info.cancerresearchuk.org/cancerstats/types/lung/?a=5441). 
As the average human life span increases with groundbreaking discoveries in the 
 7 
medical arena, mutations in cells and tissues are given enough time to develop into 
cancer. On top of that, industrializations globally, increased radiation due to ozone 
damage, extensive production of processed food and various failing personal lifestyle 
has raised the risk of various cancers in the present human population. Therefore, it is 
important to guard against cancer and the first step in doing so would be to do 
molecular imaging periodically to detect any preliminary onset symptoms of cancer. 
 
      
Figure 2.2: Causes of cancer. 
(Adapted from http://www.dmacdigest.com/cancer.html) 
 
2.3 Molecular Imaging  
Early stage diagnosis plays a key role in determining the prognosis for diseases, 
especially for fatal ailments such as cancer and cardiovascular diseases. Molecular 
imaging provides critical information necessary to diagnose a disease in its earliest 
stage, which is an in vivo characterization and measurement of the disease process at 
the cellular and molecular level. Its objective is to investigate molecular basis and 
diagnose abnormalities of cellular functions as well as follow up molecular processes 
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in living organisms in a non-invasive way. Development of novel agents, signal 
amplification strategies, and imaging technologies have been extensively made with 
prior research efforts to improve molecular imaging. 
Currently, the assessment of disease is based on anatomic or physiologic changes 
that are a late manifestation of the molecular changes that truly underlie disease. 
Direct imaging of these molecular changes will improve patient care by allowing 
earlier detection of diseases such as cancer, neurological and cardiovascular diseases. 
It may be possible to image molecular changes, allowing intervention at a time when 
the outcome is most likely to be affected. In addition, by directly imaging the 
underlying alterations of disease, it will be possible to directly image the effects of 
therapy. Therefore, it will be possible to play a direct role in determining the 
effectiveness of treatment shortly after therapy has been initiated, in contradistinction 
to the many months often required today to determine whether intervention has been 
beneficial. Molecular imaging also contributes to improving the treatment of disorders 
by optimizing the pre-clinical and clinical tests of new medication.  
To image specific molecules in vivo, various criteria must be met. These criteria are, 
availability of high affinity probes also known as biomarkers, the ability of these 
probes to overcome delivery barriers (vascular, interstitial, cell membrane), use of 
amplification strategies (chemical or biologic) and availability of sensitive, fast, high 
resolution imaging techniques  (Weissleder R et al., 2001). All four factors must be 
met for successful in vivo imaging at the molecular level. 
 
2.4 How Molecular Imaging Works 
Basically, the probes interact chemically with their surroundings and in turn alter the 
image according to molecular changes occurring within the area of interest 
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(Weissleder R et al., 2001). This process is distinctly different from previous methods 
of imaging which primarily imaged differences in qualities such as density or water 
content. Some concerns for the design of the probes are their targeting ability to areas 
where imaging are needed and also their ability to cloak from the body’s immune 
system before they reach the targeted site. 
There are various modalities of molecular imaging available currently. Different 
imagers can be utilized for different stages of radiotherapy. 
 
2.5 Molecular Imagers in Radiotherapy (RT) 
A typical process of high-precision RT techniques consists of five major phases. They 
are simulation, treatment planning, set-up verification, beam delivery and response 
assessment. For simulation phase, the patient is immobilized according to treatment 
delivery. The patient’s structural information is obtained. This information is then 
transferred to an RT planning system for the treatment-planning step in which tumor 
extension and organ at risks are identified with the target volume to be treated 
defined. Treatment parameters are determined according to the volumes defined on 
images and dose prescription. Once a plan that meets the criteria is calculated, the 
parameters of the plan are automatically transferred to the treatment machine. In the 
third phase, the patient is positioned on the treatment table for each treatment session 
in the same way as was done during the simulation. In the fourth phase, the beam 
delivery stage, the machine is operated according to the planned parameters. In 
selected cases, such as lung and liver lesions, this step can take advantage of real-time 
assessment of tumor position. Finally, the fifth phase regards the assessment of tumor 
response after RT, important in determining treatment success and in guiding future 
patient therapy (Michela L et al., 2008). Throughout the radiotherapy process, various 
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molecular imagers can be utilized. The focus of this paper will be the possible 
molecular imagers that can be utilized in the planning phase. 
 
2.6 Current Imaging Techniques  
Three medical imaging techniques, which are used most often in the current clinical 
practice, are the X-ray computed tomography (CT), positron emission tomography 
(PET) and magnetic resonance imagery (MRI). All these three imaging techniques 
involve using contrast agents.  
In CT scans, radiocontrast agents are used. They are grouped into ionic and nonionic 
agents. As they are typically iodine compounds, adverse reactions are a concern. The 
risk for adverse reaction is 4% to 12% with ionic contrast materials and 1% to 3% 
with nonionic contrast materials (Cochran ST, 2005). Besides the potential risks from 
using the radiocontrast agents, CT scans also expose patients to harmful X-ray 
radiation.  
 
Figure 2.3: CT imager. 
(Adapted from http://stardiagnostics.org/RADIOLOGY.HTML) 
 
On the same note, PET scans also involve the use of radioactive tracer isotopes to 
promote imaging. These radiotracers are extremely unstable and ionize, resulting in 
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radiation during imaging. In view of the radiation exposures of CT and PET scan, it is 
obvious that MRI is the preferred imagery technique, as it is non-invasive and will not 
cause radiation injury. 
 
  
Figure 2.4: PET imager. 
(Adapted from http://www.fmh.org/body.cfm?id=155)  
 
2.7 Magnetic Resonance Imaging (MRI)  
For the last three decades, magnetic resonance imaging (MRI) has been one of the 
more powerful imaging techniques for the examination of the human anatomy, 
physiology and pathophysiology largely due to the fact that it is non-invasive. Since 
its invention in 1973 by Paul Lauterbur, MRI has currently been widely used in 
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hospitals since its approval by the FDA for clinical use in 1985 (Yan GP et al., 2007). 
MRI images have excellent soft tissue specificity. It involves the use of a magnetic 
field, radio waves and a computer to produce detailed images of the body’s interior, 
providing great soft tissue contrast that enables the differentiation between healthy 
and abnormal tissues (cancerous cells/tumors) (Jain TK et al., 2009). 
 
  
Figure 2.5: MRI. 
(Adapted from http://brainimaging.waisman.wisc.edu/facilities/ni_facilities.html) 
   
The principle of MRI is based on the intrinsic properties of charge, spin and 
magnetism of the atomic nuclei (Jackson GD et al., 2005). The human body is largely 
composed of water molecules that contain two hydrogen nuclei or protons. When 
exposed to an external magnetic field, the energy of the nuclei will split into lower 
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(moment parallel with field) and higher (antiparallel) energy levels according to the 
Zeeman effect.  
 




The parallel alignment is the preferred stable alignment. The energy difference 
between these two energy states corresponds to a very specific frequency necessary to 
excite a nucleus from the lower to the higher state. As a result of a larger number of 




(A)                                                       (B) 
 Figure 2.7: (A) A collection of H nuclei in the absence of an externally applied 
magnetic field. (B) An external magnetic field B0 is applied which causes the nuclei 
to align themselves in one of two orientations with respect to B0 (denoted parallel and 
anti-parallel). 
(Adapted from http://www.mikepuddephat.com/Page/1603/Principles-of-magnetic-
resonance-imaging)                           
 
When a radiofrequency (RF) pulse (equal to the Larmor frequency: the frequency of 
the precession of individual nuclei around the direction of the magnetic field) is 
applied, the protons would switch from the parallel state to the antiparallel state and 
the spins are forced to precess in phase. The net magnetization (Mz) flips 90° from 




Figure 2.8: At Larmor frequency, the net magnetization flips 90° and the spins are 
forced to precess in phase. 
 
After the radiofrequency pulse is lifted, the nuclei would go back to the initial 
equilibrium state and the time taken for this process is known as the relaxation time. 
There are two states of relaxation process: transverse and longitudinal. Longitudinal 
relaxation time (T1) is the time required for the nuclei to realign to the external 
magnetic field and is defined as the time for the system to reach 63% of its 
equilibrium value after subjecting to a 90° RF pulse. On the other hand, transverse 
relaxation time (T2) is the time required for 63% of the RF generated transverse 
magnetization to dissipate which occurs due to the dephasing of the spins. As a result 
of relaxation, the energy absorbed during the application of the RF pulse will be 
released in the form of a signal that can be detected by a receiver coil. Using a 
combination of RF pulses and magnetic field gradients, an MRI image can be 
obtained due to the variation in T1 and T2 values of different tissues that in turn give 
rise to the image contrast (Van Geuns RJM et al., 1999). 
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Although MRI is presently popular due to its noninvasive property, one drawback 
of MRI is its natural insensitivity of imaging for label detection. This can fortunately 
be overcome by using targeted MRI contrast agents coupled with biologic 
amplification strategies. One example is the cellular internalization of 
superparamagnetic probes such as monocrystalline iron oxide nanoparticles (Moore A 
et al., 1998; Weissleder R et al., 2000). 
 
2.8 MRI Contrast Agents  
 In order to provide a better contrast in MRI, contrast agents are introduced. MRI 
contrast agents are substances that enhance the image contrast between healthy and 
abnormal tissues. Most MRI contrast agents achieve that by altering the relaxation 
times of the water protons in places where the agents accumulate. 
MRI contrast agents are split into two groups: T1-agents and T2-agents. T1-agents 
increase the longitudinal relaxation rates of protons more than the transverse 
relaxation rates. They reduce T1 relaxation time more than T2. Therefore, they tend to 
increase the signal intensity and make the MRI images appear brighter. Due to this 
effect, T1-agents are also known as positive contrast agents (Yan GP et al., 2007). 
Examples of T1-contrast agents are paramagnetic metals such as gadolinium, 
manganese and dysprosium. These free metals, in their ionic states, are not suitable 
contrast agents due to their toxicities and undesirable biodistribution. To utilize these 
agents, ligands must be treated with these metal ions to form chelates. In this way, 
kinetically stable complexes can be formed which can be excreted intact, decreasing 
their toxicity. 
On the other hand, T2-agents increase the transverse relaxation rates more than the 
longitudinal relaxation rates. They reduce T2 relaxation time more than T1. The 
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signal intensity is reduced upon T2-agents applications and the MRI images appear 
darker. As a result, they are also known as negative contrast agents (Yan GP et al., 
2007). Examples of T2-agents are superparamagnetic iron oxides. 
 
  
Figure 2.9: Axial T1 weighted (A) and T2 weighted (B) images of the brain magnetic 
resonance imaging (MRI) demonstrating a lacunar infarction (arrow). 
(Adapted from http://casereports.bmj.com/content/2009/bcr.04.2009.1754.full) 
  
2.9 Superparamagnetic Iron Oxide (IO)  
Superparamagnetic iron oxide (IO) is widely used as a contrast agent for MRI. Most 
superparamagnetic iron oxides include cores consisting of iron oxides of 2-20 nm. 
They are usually made soluble and biologically stable via means of organic coatings. 
These organic coatings are commonly dextran or polyethylene glycol. As 
superparamagnetic IO is more effective in reducing T2 relaxation time, the images 
obtained when using superparamagnetic IO particles as contrast agents will be darker 
at the parts where they accumulate (Sahana D et al., 2008).  
 18 
When compared with other MRI contrast agents, superparamagnetic IO appears to be 
superior, exhibiting some favorable magnetic properties and acceptable 
biocompatibility. Firstly, it can vastly enhance imaging due to its exceptional 
penetration depth. Secondly, superparamagnetic IO has zero retained magnetism after 
the removal of magnetic field (Mu L et al., 2002). On top of that, its uptake by 
macrophages and migration to the lymph modes also make them widely used for 
nodal staging (Molday RS et al., 1982). However, IO has some disadvantages, which 
limit their application in biomedical arena. Disadvantages include instability, fast 
excretion by the RES, limited sensitivity and cytotoxicity (Govender T et al., 1999; 
Zhang Z et al., 2006; Maeda H, 2001; Park JH et al., 2008).  
A few superparamagnetic IO contrast agents were developed for MRI. These probes 
enable clearly defined anatomy imaging post contrast. Imaging molecular targets for 
early stage disease diagnosis requires probes with greater ability to amplify MRI 
signals (Weissleder R et al., 2001; Lee SJ et al., 2005).  Besides IOs, another probe 
used for amplification strategy is quantum dots (QDs) as luminescence probes in 
fluorescence imaging. 
 
2.10 Fluorescence Imaging  
Fluorescence imaging is one of the major techniques in optical imaging. It is widely 
used in molecular biology and biochemistry laboratories. It can be applied in a large 
number of experimental, analytical and quality control applications. Besides probable 
side effects from the probes used, fluorescence imaging virtually has no other adverse 
effects and definitely does not involve radiation like most imaging techniques. 
Compared to other imaging modalities, fluorescent imaging modality has several 
important advantages including high sensitive detection, multicolor detection, probe 
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stability, low hazard and low cost (Liu Z et al., 2010). On the other hand, fluorescent 
imaging also has some disadvantages such as photobleaching, limited tissue 
penetrating depth, surface-weighted, relatively low spatial resolution and auto 
fluorescence disturbance (Liu Z et al., 2010). In view of these disadvantages, contrast 
agents such as organic fluorescent dyes and Quantum Dots (QDs) are often used to 
promote the fluorescence imaging. 
 
 
Figure 2.10: IVIS Fluorescence imager. 
(Adapted from http://www.aomf.ca/xenogenname.html) 
 
2.11 Fluorescence Imaging Principle 
Fluorescence imaging works based on quantum theory. The contrast agents absorb a 
specific light frequency that is emitted from a proper imaging instrument to exactly 
raise their energy level to a brief excited state. Subsequently, these contrast agents 
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emit a fluorescent light whose wavelength is different from that of the absorbed light 
as they decay from this excited state as illustrated below. The imaging instrument 
detects this fluorescent light and based on the fluorescence signal from the whole 
sample, a fluorescent image is generated. The most often used fluorescent imaging 
instruments are wide field microscopes, confocal laser scanning microscopy, multi-
photo microscopy, and deconvolution and 3D/4D image processors (Liu Z et al., 
2010; Agarwal A et al., 2008). 
 
 
Figure 2.11: Jablonski diagram illustrating the processes involved in creating an 
excited electronic singlet state by optical absorption and subsequent emission of 





2.12 Quantum Dots (QDs) 
Quantum dots (QDs), also known as fluorescent semiconductor nanocrystals, are 
composed of atoms from groups II-VI or III-V of the periodic table. Cadmium 
selenide (CdSe), cadmium telluride (CdTe) and indium arsenide (InAs) are examples 
of fluorescent QDs that are most often used (Mishra B et al., 2010; Peng ZA et al., 
2001). Various synthesis methods have been formulated to produce different forms of 
QDs. Such methods include colloidal synthesis, viral assembly, electrochemical 
assembly and bulk-manufacture. Among these, colloidal QDs, synthesized from 
colloidal synthesis, are most widely used. 
QDs are predominantly spherical in shape with sizes ranging from 1 to 12 nm. They 
contain fluorophore, a molecule responsible for its luminescent properties. These 
luminescent properties are resulted from the quantum confinement effects. Upon 
irradiation, QDs absorb energy (at any wavelength greater than the energy of their 
lowest energy transition) and convert the energy into an extremely narrow bandwidth 
emission close to the band edge (Green M et al., 1999; Murray CB et al., 2000; 
Sutherland AJ, 2002). 
 
2.13 Optical Properties of Quantum Dots (QDs) 
Quantum dots are regarded to be the more superior fluorescent probes as compared to 
organic dyes (other fluorescent probes used popularly for bio-imaging). QDs have 
several outstanding optical advantages that make them excellent for biomedical 
applications. In vivo longevity is one major advantage of QDs, which enables 
extended applications in vivo, differentiating QDs from other fluorescent probes 
(Ballou B et al., 2004). Tunable emission from visible to infrared wavelength by 
changing the size and composition of QDs is another advantage of QDs. For instance, 
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CdSe QDs with a 2 nm diameter emit green light with a wavelength of 550 nm, 
whereas larger CdSe QDs with a 4 nm diameter emit lower energy red light with a 
wavelength of 630 nm (Sutherland AJ, 2002; Bruchez M et al., 1998). Apart from 
that, QDs also have broad excitation spectra with high absorption coefficients, high 
quantum yield of fluorescence, strong brightness, high resistance to photobleaching 
and good sensitivity (Pan J et al., 2008; Kim S et al., 2004; Gao XH et al., 2004).  
 
  
Figure 2.12: Excited quantum dots arranged according to size. 
(Adapted from http://www.elec-intro.com/quantum-dots) 
 
2.14  Applications of Quantum Dots (QDs) 
As a result of the many optical advantages, QDs have been widely studied and 
utilized in many biomedical areas especially for bio-imaging. For instance, it is 
reported that QDs can be applied in fluorescent labeling for both in vivo cellular and 
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molecular imaging and in vitro assay detection. Besides that, QDs have also been 
used to trace cell line age, monitor physiological events in live cells, track cells in 
vivo, specifically mark cellular and molecular structures and measure cell mortality 
(Pan J et al., 2008). On top of that, QDs are also employed in DNA hybridization 
detection (Parak WJ et al., 2002). Luminescent colloidal semiconductor nanocrystals 
which contain CdSe-ZnS core-shell QDs are widely used for fluoroimmunoassay 
(Goldman ER et al., 2002) while QDs conjugated with internalin A and internalin B 
are used to detect food toxins (Gao XH et al., 2004). Various other applications of 
QDs are shown in the figure below:  
 
 
Figure 2.13: QDs applications (Michalet X et al., 2005).  
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2.15  Limitations of Quantum Dots (QDs) 
QDs have been widely studied in many biomedical applications as a result of their 
various advantages. However, QDs usage does exist some limitations. One limitation 
is that the biocompatibility of QDs still remains rather unknown. The 
pharmacokinetic processes-absorption, distribution, metabolism and excretion 
(ADME) of QDs have not been explored nor understood. Generally, QDs may 
possibly have some toxic effects on the human body (Pan J et al., 2008). One report 
that led to this suspicion is a finding that reported CdSe/ZnS QDs to be toxic because 
of their release of Cd2+ ions. The Cd2+ ions are formed by surface oxidation of the 
QDs (Derfus AM et al., 2004). It is reported that CdSe QDs are highly toxic to 
cultured cells under UV illumination for prolonged periods. The CdSe QDs release 
toxic Cd2+ ions by photolysis under UV illumination as shown below: 
 
 
Figure 2.14: CdSe QDs release of toxic Cd2+ ions by photolysis under UV 
illumination (Derfus AM et al., 2004). 
 
Besides toxicity related issues, another limitation of QDs is that their solubility in 
aqueous buffer is rather low. Normally, QDs are synthesized in hydrophobic organic 
solvents. Therefore, a layer of hydrophobic organic ligands is formed on their surface. 
As a result of this hydrophobic layer, QDs are insoluble in aqueous buffers and their 
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applications in the biological condition are therefore limited. Another limitation of 
QDs is that they have difficulties penetrating physiological drug barriers, resulting in 
low cell uptake efficiency. Last but not least, a major limitation is that QDs are fast 
excreted by the reticuloendothelial system (RES) (Pan J et al., 2008). This may result 
in QDs having short circulation time meaning that insufficient amount of the probe 
would find their way to the intended imaging site, resulting in poor imaging. QDs can 
be successfully applied in biology and medicine if these problems are solved.  
 
2.16  Challenges of QDs and IO application in Imaging 
2.16.1 Insufficient Probes at Imaging Site 
Although necessary, amplification strategies are not enough to produce high quality 
images. Sufficient concentrations of probes must be gathered at the intended imaging 
area for an adequate period in vivo. Nevertheless, the agent dose is limited by the side 
effects of the agent itself and the rapid removal of probes from the blood system due 
to the body’s mononuclear phagocyte system (MPS) interactions after opsonization 
(Puisieux F et al., 1994; Stolnik S et al., 1995). 
2.16.1.1 Mononuclear Phagocyte System (MPS) 
Although some probes may prove to be useful in binding to the targeted area of the 
body where imaging is intended in in vitro tests, they may have limited use due to 
their rapid removal from the blood system in vivo. This is due to interactions with the 
human body’s mononuclear phagocyte system (MPS) (Puisieux F et al., 1994; Stolnik 
S et al., 1995) with the probes after opsonization. Phagocytes will attach to the 
opsonized foreign bodies when the attached opsonin proteins undergo conformational 
changes to form activated proteins detectable by phagocyte receptors (Donald E et al., 
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2006). Non-specific attachment of phagocytes can also occur due to association of 
opsonin proteins on the hydrophobic foreign particle surface (Donald E et al., 2006; 
Frank M and Fries L, 1991). Complement activation, activated by one of several 
mechanisms including the classical, alternative and lectin pathway (Donald E et al., 
2006; Puisieux F et al., 1994) also aids phagocyte attachment. Lastly, phagocytes 
engulf foreign particles by a process of endocytosis and commence secretion of 
enzymes and oxidative-reactive chemical factors such as superoxides and hydrogen 
peroxides to break down the particles (Donald E et al., 2006, Stolnik S et al., 1995). 
 
 
Figure 2.15: Opsonization and Phagocytosis of a bacteria. 




2.16.1.2 Methods to Cloak Nanoparticles 
Hence, it is evident that probes, which are not protected when injected into the body, 
can be swiftly removed by the MPS within a matter of seconds, rendering them 
ineffective (Gref R et al., 1994). Macrophages recognize probes as foreign entities 
due to the activated opsonin proteins, which are attached to the particles (Donald E et 
al., 2006). It is possible to devise methods to cloak nanoparticles and enable them to 
bypass MPS recognition, increasing their blood circulation half life (Illum L et al., 
1984; Gref R et al., 1994; Kaul G et al., 2002). Methods to cloak nanoparticles from 
MPS recognition and therefore increase their half-life in circulation involve surface 
modification of the probes (Gref R et al., 1994; Illum L et al., 1984; Kaul G et al., 
2002) to prevent opsonin proteins in the blood from being attached to the particles 
surfaces thus, escaping MPS detection. 
Till now, there are no absolute solutions in completely preventing opsonization of 
particles. However, three decades of research has consolidated some trends and ways 
to hinder and slow down opsonization to increase circulatory time. Generally, 
hydrophilic particles opsonize slower than hydrophobic particles (Carstensen H et al., 
1992; Muller RH et al., 1992; Norman ME et al., 1992) and neutrally charged 
particles opsonize slower than charged particles (Roser M et al., 1998). Therefore, 
non-charged, hydrophilic groups have been explored for grafting onto probes to 
hinder opsonization. These groups are usually long, flexible hydrophilic polymer 
groups and non-ionic surfactants that can shield hydrophobic and charged particles 
from opsonin proteins (Stolnik S et al., 1995). 
Some proteins have been studied for their shielding properties and some have shown 
positive results. For example, chemically modified protein (bovine serum albumin) – 
coated QDs are stable for more than 2 years in buffer solution (Gao XH et al., 2002). 
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In addition to proteins, biodegradable polymers such as poly (lactic acid) (PLA) and 
poly(lactic-co-glycolic acid) (PLGA) and various biodegradable copolymers such as 
poly(lactic acid)-poly (ethylene glycol) (PLEA) copolymer and poly (lactide acid)-d-
α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) copolymer have been 
used as shielding groups. One example of the use of shielding groups is this study in 
which polyethylene glycosylation was used to prolong the circulatory stability of 
recombinant human butyrylcholinesterase (Chilukuri N et al., 2005). The PEGylated 
particles were found to have an increased of circulation time from 18.3 h to 36.2 h in 
mice. Nanoparticle formulation using copolymers such as PLA-TPGS as 
encapsulating medium and shielding outer layer, can not only protect the particles 
from MPS, but also improve the water solubility of contrast agents such as QDs and 
IO. Encapsulation using PLA-TPGS for instance can improve the stability of QDs and 
IO and prolong the circulation lifetime of QDs and IO. On top of that, the 
nanoparticle formulation may improve the contrasting effect of QDs and IO compared 
to directly using commercial QDs and IO (Wang Y et al., 2008). As shown in the 
figure below, the IO-loaded biodegradable nanoparticles have better contrasting effect 






Figure 2.16: In vitro MRI of commercial IO (Resovist) and IO-loaded PLGA-mPEG 
nanoparticles suspended in water (TE=7 ms) (Wang Y et al., 2008). 
 
In fact till date, the most effective and most commonly used polymers as shielding 
groups are the PEG and PEG-containing copolymers. Experimental research has 
visually demonstrated the shielding ability of PEGylated surfaces from opsonin 
protein attachment with the use of freeze fracture transmission electron microscopy 
(TEM) (Peracchia MT et al., 1999).  
In summary, hydrophilic particles opsonize slower than hydrophobic particles 
(Carstensen H et al., 1992; Muller RH et al., 1992; Norman ME et al., 1992) and 
neutrally charged particles opsonize slower than charged particles (Roser M et al., 
1998). Thus, non-charged, hydrophilic groups can be grafted onto the probes to hinder 
opsonization. These groups are usually long hydrophilic polymers and non-ionic 
surfactants, which can shield hydrophobic and charged particles from opsonin 
proteins (Stolnik S et al., 1995). To date, the most popularly used shielding groups are 
polyethylene glycol (PEG) and PEG-containing copolymers. One important example 
of such a copolymer is poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 
1000 succinate (PLA-TPGS) that is gaining popularity in the research scene today. 
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2.16.2 Cytotoxicity 
In addition, certain probes may have very good affinity with certain targets of 
imaging interest however they may pose to be toxic to the body. Hence, to make use 
of such probes, nanoparticle encapsulation by means of PEGylation may be needed as 
part of designing to reduce cytotoxicity of such probes. Derfus et al. demonstrated 
that the CdSe/ZnS quantum dots used as luminescence probes are highly toxic for the 
cells in culture as a result of the release of Cd2+ ions, caused by surface oxidation of 
quantum dots, and that the surface oxidation was repressed by coating with 
appropriate shells, decreasing the cytotoxicity of quantum dots. The reported surface 
coating work includes encapsulating quantum dots with dendrimer-like compounds, 
glass and amphiphilic polymers (Derfus AM et al., 2004). In 2005, Parak et al. 
extended the study of Derfus et al. and described that amphiphilic polymer-coated 
CdSe/ZnS nanocrystals in low concentrations could effectively prevent the release of 
Cd2+ ions from quantum dots surfaces, reducing their cytotoxicity (Kirchner C et al., 
2003). In addition, more recently, Yan Wang et al., indicated in their paper that their 
iron oxide (IO) loaded PLGA-mPEG nanoparticle formulation achieves 36.9% and 
35.6% less cytotoxicity after 48 h incubation at 20 and 50 µg mL–1 Fe concentrations 
as compared to non-encapsulated IO particles of the same concentrations, 
respectively. Thus, reinstating the point that encapsulation with polymers reduces 
cytotoxicity (Wang Y et al., 2008). 
The other method to decrease cytotoxicity is by targeted delivery. Targeting delivery 
of substances, in our case, contrast agents such as QDs or IO, can decrease their toxic 
effect on healthy cells. Targeting can be divided into passive targeting and active 
targeting (Pan J et al., 2008). 
 31 
2.16.2.1 Tumor Targeting 
The ability of the nanoparticles to reach the intended tissues/tumors is vital both in 
diagnostic imaging and drug delivery. Non-specificity of the nanoparticles can cause 
them to bind to healthy tissues and risk damaging them. To limit non-specific binding, 
nanoparticles can be modified to increase its affinity for the target tissues. This can be 
done in two ways: passive and active targeting. 
2.16.2.2 Active Targeting 
Cancer cells often over express either proteins that are usually found at low levels on 
healthy cells (tumor-associated antigens) or proteins that can be found only on cancer 
cells (tumor-specific antigens). Active targeting works by attaching ligands to a 
targeting component that binds with antigens expressed on the target tissue. This 
would direct the drugs or contrast agents towards the targeted organ, tissue or cells 
and cause them to accumulate at these sites. Active targeting allows the drugs/contrast 
agents to be delivered to the intended site, which reduces the side effects as well as 
promotes cellular uptake of these loadings by receptor-mediated endocytosis. 
Receptor-mediated endocytosis is the process whereby the ligands bind to the 
receptors on the cell surface followed by internalization through coated pits and 
vesicles into the cells (Park JH et al., 2008). 
 
2.16.2.3 Passive Targeting 
In passive targeting, the nanoparticles (QDs and IO loaded PLA-TPGS in our case) 
accumulate at the tumor through the enhanced permeability and retention (EPR) 
effect. Tumor blood vessels differ from normal blood vessels in which there are a 
relatively high proportion of fast growing endothelial cells, increased irregularity, 
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pericyte deficiency and abnormal basement membrane formation. Cancer cells require 
lots of oxygen and nutrients for their rapid growth. This in turn stimulates fast 
production of blood vessels. Vascular structures resulted from rapid growth, are 
defective and lack effective lymphatic drainage system, rendering the vessels 
permeable to macromolecules and small particles. Because of the lack of efficient 
lymphatic drainage, these particles cannot be cleared effectively and hence 
accumulate in the tumor. This effect is known as the enhanced permeability and 
retention effect (Maeda H, 2001). As our hypothesized probe system does not include 




Figure 2.17: Passive and active tumor targeting. 
(Adapted from http://www.ajnr.org/cgi/content/full/30/7/1293/F2) 
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2.17  Nanotechnology in Molecular Imaging 
As mentioned earlier, the first factor for molecular imaging to be possible is the 
presence of high affinity probes with reasonable pharmacodynamics. Such probes 
used are usually nanoparticles. Nanoparticles are basically particles sized between 1 
and 100 nanometers. Their size limitation can be restricted to two dimensions and 
they may or may not exhibit size-related properties that differ significantly from those 
observed in fine particles or bulk materials.  
The nanoparticle probes used for molecular imaging can be small molecules such as 
receptor ligands or bigger higher molecular weight affinity ligands such as 
recombinant proteins. The advantage of synthesizing imaging probes into 
nanoparticles is that the probes when reduced to such a small scale will not only be 
able to escape MPS detection (increasing circulation time) but also have a higher 
probability of being uptaken by cells.  
Advances in drug discovery technology today have made the discovery of potential 
affinity ligands very effective and efficient against the thousands of targets where 
imaging may be of interest. Further design and refining efforts are made on these 
potential ligands before they can be used as probes for molecular imaging. 
 As discussed earlier, certain probes may have good affinity with certain targets of 
imaging interest but pose to be toxic. An example is QDs, which are made up of 
elements that are toxic in individual elemental form. An appropriate modification and 
formulation of QDs could minimize their toxicity (Gao XH et al., 2005; Wang X et 
al., 2008).  Formulation of imaging probes such as IOs and QDs in nanoparticles of 
biodegradable polymers may thus provide an ideal solution as well as enhance 
cellular uptake, hence improving imaging effects (Wang Y et al., 2008). Moreover, 
the imaging agent-loaded nanoparticles can be further conjugated with biological 
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ligand to realize targeted delivery of the imaging agent to the diseased cells, which 
can be distinguished from healthy ones. The nanoparticles surface decorated with 
targeting ligand enables the selective delivery of imaging agent into diseased cells by 
the ligand-mediated approach, which achieves high specificity and sensitivity of 
cancer detections, allowing the diagnosis of cancer at its earliest stage.  
 
2.18 Multi-modality 
IO and QD probes are effective probes for amplification in molecular imaging. 
However, individual imaging probes have their advantages and disadvantages. No 
single imaging modality is perfect to satisfy all the requirements for bio-imaging. For 
instance, IO probes provide high spatial resolution and unlimited depth penetration 
(Medarova Z et al., 2006) but their sensitivity in imaging fails in comparison to 
optical fluorescence imaging probes such as QDs. QDs, in turn; have excellent 
imaging effects and long half-life, but their ability for tissue penetration is limited due 
to the refraction and adsorption of light in the living organism. Therefore, it is very 
important to find an imaging method that can fulfill the requirements in medical 
applications as much as possible, and this can be achieved by applying multi-modal 
imaging.  
Multi-modal imaging means applying two or three or even more imaging modalities 
concurrently. Multimodal imaging can be developed to make use of the advantages 
and overcome the limitations, which can be realized by co-encapsulation of QDs and 
IOs in ligand-conjugated nanoparticles of biodegradable polymers.   
There have been some studies involving remodelling imaging probes suited for dual 
modality imaging capabilities. Xie J et al. encapsulated dopamine modified IO 
nanoparticles into HAS matrices which permit applications in MRI. Such HAS-IO 
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nanoparticles were labelled with Cy5.5 dye and 64 Cu-DOTA chelates which permits 
applications in NIRF imaging and PET imaging respectively (Xie J et al., 2010).  
 
Figure 2.18: Schematic illustration of the multi-functional HSA-IONPs. The 
pyrolysis-derived IONPs were incubated with dopamine, after which the particles 
became moderately hydrophilic and could be doped into HSA matrices in a way 
similar to drug loading  (Xie J et al., 2010). 
  
In this triple modality system, MRI offers a high spatial resolution. However, MRI 
has the issue of limited sensitivity. Therefore, PET and NIRF were utilized to 
compensate for this drawback. Between these two, PET provides a better signal-to-
noise ratio. NIRF, on the other hand, can be visualized both in vivo by an IVIS system 
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and ex vivo by fluorescence microscopy, playing a unique role of bridging the in vivo 
and histological observations.  
In another study by Zhou et al., the concept of upconversion luminescence (UCL) and 
MR dual-modality imaging in vivo of whole-body animals was explored. In the work, 
Tm3+/Er3+/Yb3+ co-doped NaGdF4 was synthesized with near-infrared to near-
infrared upconversion luminescent and magnetic resonance properties (Zhou J et al., 
2010). Also, Choi et al. explored hetero-structured complexes formed by magnetic 
iron oxide nanoparticles and near-infrared (NIR) fluorescent single-walled carbon 
nano-tubes (SWNT) (Choi JH et al., 2007). These complexes, when further 
conjugated with monoclonal antibodies to target specific receptor site, could be used 
to provide molecular-level contrast and bio-sensoring.  
In another multi-modal study, Rieter, WJ et al. found that hybrid silica nanoparticles 
could also be used as multi-modal contrast agents for in vitro optical and T1-and T2-
weighted MRI (Rieter WJ et al., 2007). Each hybrid silica nanoparticle contains a 
luminescent [Ru(bpy)3]Cl2 core (bpy=2,2’-bypyridine) and a paramagnetic monolayer 
or multilayer coating of a silylated Gd complex. The luminescent core acts as a 
contrast agent for optical imaging and Gd3+ (containing microemulsions) acts as a T1 
contrast agent. The optical imaging has high sensitivity while MRI has high spatial 
resolution. The dual modalities system can have high sensitivity as well as high 





Figure 2.19: Synthesis of hybrid silica nanoparticles (Rieter WJ et al., 2007). 
 
Hwang DW et al also developed a nucleolin-targeted multimodal nanoparticle-
imaging probe for tracking cancer cells using an aptamer. This multimodal 
nanoparticle-imaging probe can be used in fluorescence imaging, radionuclide 
imaging and MRI in vivo concurrently (Hwang DW et al., 2010). 67Ga-
MNP@SiO2(RITC)-PEG/NH2-AS1411 (MFR -AS1411) nanoparticles are made up of 
magnetic cobalt ferrite in the central core and rhodamine B isothiocyanate 
fluorescence dye (MF) coated with a silica shell. In addition, polyethylene glycol 
(PEG), Fmoc-protected amine moieties, and a carboxyl group surround the surface of 
the particles, which were further labeled with AS1411 aptamer, p-SCN-bn-NOTA 





Figure 2.20: Schematic illustration of MFR-AS1411 synthesis. MF particles had 
carboxyl group and Fmoc-protected amine moiety, which was coupled with amine 
terminated AS1411 aptamer using EDC (MF-AS1411). After reaction of MFAS1411 
with p-SCN-bn-NOTA, particles were reacted with 67Ga-citrate to form MFR-
AS1411 (Hwang DW et al., 2010).  
 
The magnetic cobalt ferrite is the contrast agent for MRI. MF is the contrast agent for 
fluorescence imaging and 67Ga-citrate is the contrast agent for radionuclide imaging. 
This multi-modal imaging system offers a broad range of imaging possibilities, 
ranging from in vitro cellular studies using fluorescence materials to bioluminescence 
imaging in animal models and radionuclide and MRI for potential diagnostic and 
therapeutic human application (Hwang DW et al., 2010). 
To achieve a thorough analysis of one multi-modal imaging system, in vivo, ex vivo 
and in vitro analyses should be done and cross-referenced. Most of the studies listed 
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above, however, are related either to ex vivo or in vitro analysis. Most of them were 
lacking in in vivo analysis. Furthermore, some of the studies lack clinical feasibility as 
they involve the use of probes for imagers, which are either not available or 
impractical in the current medical scene. In addition, some imaging modalities such as 
CT and radionuclide imaging explored have significant side effects on human health.  
As mentioned before, both fluorescence imaging and MRI are non-invasive and will 
not cause radiation injury. On top of that, the QDs and IO as contrast agents for 
fluorescence imaging and MRI respectively have been widely studied in biomedical 
applications. Therefore, encapsulation both QDs and IO in PLA-TPGS copolymers as 
multi-modal imaging probes should provide high quality images. This multi-modal 
imaging probe should have high sensitivity and depth penetration. 
In this study, IO contrast agent and fluorescence QDs are co-encapsulated in a 
biodegradable polymer, poly(lactide)—tocopheryl polyethylene glycol succinate 
(PLA-TPGS), which was a new type of biodegradable copolymer synthesized in our 
laboratory (Zhang Z et al., 2006). PLA provides the needed mechanical strength and 
enough biodegradability for extended blood circulation times, while  TPGS 
component reduces cytotoxicity and provides stealth from RES as well as enhances 
chemotherapy by inhibiting P-gp activity, i.e. the multiple drug resistance (MDR) 
effects (Dintaman JM et al., 1999; Johnson BM et al., 2002). The IOs and QDs were 
encapsulated in the polymer matrix of PLA-TPGS by a modified nanoprecipitation 
technique. Particle characterization was performed and the probe was tested in vitro 
for cytotoxicity and cell uptake. Furthermore, the multimodal probe was tested in vivo 
on tumor xenograft grown on immune deficient mice. This multimodal probe enabled 
tumor visualization for both MRI and fluorescent imaging. The results showed that 
the multimodal probe could provide an enhanced avenue for a more detailed imaging 
 40 
procedure, reducing the possibility of overlooking any inherent problem which may 
have been the result of poor imaging due to limitations of using a single modality 
probe.  
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CHAPTER 3: MATERIALS & METHODS 
3.1 Materials 
 
Organic Quantum Dots (Qdot®655 ITK™; catalog number Q21721MP) and Carboxyl 
Quantum Dots (Qdot®655 ITK™; catalog number Q21321MP) were purchased from 
Invitrogen Corporation Singapore. Iron Oxide (IO) dispersed in THF is prepared from 
Resovist® provided by a colleague from another laboratory. Tetrahydrofuran (THF), 
Penicillin-streptomycin solution and trypsin–EDTA solution were provided by 
Sigma–Aldrich (Sigma–Aldrich Pte Ltd, Singapore). Fetal bovine serum (FBS) was 
purchased from Gibco (Life Technologies AG, Switzerland). DMEM medium was 
from Invitrogen Corporation. All chemicals used in this study were HPLC grade. 
Millipore water was produced by the Milli-Q Plus System (Millipore Corporation, 
Bedford, USA). MCF-7 breast cancer cells were provided by American Type Culture 
Collection. PLA-TPGS copolymer was synthesized according to a method described 
in our previous work (Zhang Z et al., 2006; Prashant C et al., 2010). The PLA:TPGS 
component ratio for the PLA-TPGS copolymer used in this research is 90:10 w/w. 
Nuclear magnetic resonance spectroscopy (NMR) testing on the copolymer revealled 






3.2 Synthesis Methods 
3.2.1 Flocculation of QDs 
The Organic QDs from Invitrogen were dispersed in n-decane. To prepare the QDs in 
THF, 1200 µL of alcohol mixture (75% methanol: 25% propanol) was added to 200 
µL of organic QDs (equivalent of 0.23 mg Cd as determined by ICP-MS). The 
solution was then vortexed for 2 minutes and subjected to centrifuging for 15 minutes 
at 11,000 rpm. The supernatant was removed and 1 mL of THF was added to disperse 
the QDs. 
3.2.2 Formulation of QDs and IOs-loaded NPs 
 
The QDs and IOs-loaded NPs were prepared by a modified nanoprecipitation method 
(Prashant C et al., 2010). The previously flocculated QDs were dispersed in 1 mL 
THF (equivalent of 0.23 mg Cd as determined by ICP-MS), 20 µL of IOs solution in 
THF (containing 1 mg of IO) and 100 mg of PLA-TPGS copolymer were dissolved in 
5 mL THF. The resulting solution was poured gradually into 30 mL of aqueous phase 
containing 15% (w/v) TPGS as emulsifier. The mixture was then sonicated at 25 W 
output until homogeneity was achieved and then diluted with water to aid diffusion of 
the organic solvent and precipitation of the nanosized particles. The resultant solution 
was stirred continuously overnight to allow the organic solvent (THF) to vapourize. 
The particle suspension was centrifuged at 10,500 rpm for 15 min to obtain the NPs in 
the pellet. The NPs were washed thrice with deionized (DI) water and subsequently 





3.3 Characterization of QDs and IOs-loaded NPs: 
 
3.3.1 Particle Size and Size Distribution 
 
The average particle size and size distribution of the QDs and IOs-loaded PLA-TPGS 
NPs were measured using laser light scattering (LLS, 90 Plus Particle Size, 
Brookhaven Instruments Co., USA). The NPs were diluted with DI water and 
sonicated for 2 minutes before measurement. 
 
3.3.2 Surface Charge 
 
The zeta potential of the QDs and IOs-loaded PLA-TPGS NPs was determined with 
ZetaPlus zeta potential analyzer (Brookhaven Instruments Corporation) at room 
temperature. The samples were diluted with DI water before measurement. Six 
measurements were taken and the average was recorded. 
 
3.3.3 TEM Analysis 
 
The shape of the PLA-TPGS NPs and the encapsulation of the IOs and QDs were 
verified by transmission electron microscope (TEM, JEM-2010F, JEOL, Japan). For 
the preparation of TEM samples, drops of diluted NPs were added onto the surfaces 
of formvar-coated copper grids. The NPs were left to dry at room temperature. 
 
3.3.4 QDs and IOs Encapsulation Efficiency 
 
The encapsulation efficiencies of QDs and IO in the PLA-TPGS NPs were evaluated 
using the inductively coupled plasma mass spectrophotometer (ICP-MS, Model: 
Agilent Technologies 7500 series G3271A). A known amount of the QDs and IOs-
loaded PLA-TPGS NPs was dissolved in 1 mL of reagent grade 65% nitric acid and 
boiled for 2 h at 80 °C. The resultant solution was then diluted with MilliQ water to 
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the desired volume for ICP-MS analysis to determine the actual amount of the 
Cadmium (from QDs) and Fe (from IOs) encapsulated in the NPs. The dosages of 
QDs and IOs were also prepared separately in the same way for ICP-MS analysis to 
determine the actual amount of individual Cd (from QDs) and Fe (from IO) added 
during particle synthesis. The intensities obtained were compared to that of the Cd 
and Fe standards for quantization (Sigma-Aldrich, Singapore). The percentage QDs 




To confirm that the IO and QDs detected from the synthesized nanoparticles were 
encapsulated within the nanoparticles and not merely on the surfaces of the particles, 
the particles are sent for X-ray photoelectron spectroscopy (XPS) testing. X-ray 
photoelectron spectroscopy (XPS) can be applied to determine the elements or 
components presented on the surface of a compound within a depth range of 1 to 10 
nm. The samples are prepared simply by dropping a small drop of the samples on a 
piece of glass chip. The sample particles were also crushed to release the IO and QDs 















3.4  Cell Line Experiment 
 
3.4.1 Cell Cultures 
 
The MCF-7 breast cancer cells used in the cell studies were cultured using DMEM 
medium supplemented with 10% FBS and 1% antibiotics. The cells were cultivated at 
37 °C in humidified environment of 5% CO2. The cells were pre-cultured until 
confluence was reached before they were used for in vitro studies (Win KY et al., 
2005). 
 
3.4.2 In vitro cellular uptake of NPs 
 
For qualitative study, MCF-7 cells were cultivated in the chambered cover glass 
system (LAB-TEK®, Nagle Nunc International, Rochester, NY) with 5% CO2 in 
DMEM at 37 °C as proposed by American Type Culture Collection. After 24 h 
incubation time, the adherent cells were washed twice with PBS and 50 µL of QDs 
and IO-loaded NPs (diluted to have the NPs of QDs equivalent to 1 µg Cd in 1 mL of 
media) were added into the chambers. The cells were incubated with the NPs for 4 h 
and were washed 4 times with PBS after incubation. They were then fixed by 70% 
ethanol for 15 minutes. The cells were washed twice again with PBS and the nuclei 
were stained with 4,6-Diamidino-2-phenylindole dihydrochloride (DAPI) for 30 
minutes. Following this, the cells were washed twice with PBS and observed using 
the confocal laser-scanning microscope (CLSM, Olympus Fluoview FV1000, Japan). 
For quantitative study, MCF-7 cancer cells were incubated in 96-well black walled 
plates (Nunc, Roskilde, Denmark) with the cell density in the range of 40,000 – 
50,000 cells/mL. After 24 h, the old medium of the sample wells was discarded and 
the cells were incubated for 1, 2 and 4 h respectively in 100 µL of QDs and IO-loaded 
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NPs of concentrations containing 1 µg/mL Cd, 0.5 µg/mL Cd and 0.25 µg/mL Cd 
dispersed in the medium. Wells of cells used as the control had their old medium 
removed and topped up with 100 µL of QDs and IO-loaded PLA-TPGS NPs of the 
respective QD concentrations dispersed in PBS.  After 1, 2 and 4 h respectively, the 
sample wells were washed thrice with PBS and finally filled with 100 µL of PBS. 50 
µL of 0.5% triton X-100 in 0.2 N NaOH was added to all the wells. The fluorescence 
intensities of the cells were measured using the microplate reader (Genios, Tecan, 
Männedorf, Switzerland). The excitation wavelength was set at 530 nm and emission 
wavelength at 652 nm. The cell uptake was calculated using the formula below: 
                  Cell Uptake (%)= (InS / InC)×100                    (3.1) 
where InS is the fluorescence intensity of the cells in the sample wells and InC is the 
fluorescence intensity of the cells in the wells acting as controls. 
 
3.4.3 In vitro Cytotoxicity 
  
MCF-7 cancer cells were incubated in 96-well black walled plates (Nunc, Roskilde, 
Denmark) with the cell density in the range of 40,000 – 50,000 cells/mL. After 24 h, 
the old medium was discarded and the cells were incubated for 24 or 48-h intervals. 
In each case, the cells were treated in the free QDs (containing 1.42 µg/mL Cd); free 
IO (containing 5.73 µg/mL Fe) or the QDs and IOs-loaded PLA-TPGS NPs 
(containing 1.42 µg/mL Cd and 5.73 µg/mL Fe) dispersed in the medium. At the 24 h 
and 48 h intervals, the cultured cells were assayed for cell viability with 
methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma). The wells were washed 
twice using PBS and then 10 µL of MTT supplemented with 90 µL culture medium 
was added into each well. After 24 h or 48 h incubation in the incubator, the culture 
medium was removed and the purple crystals were dissolved in DMSO. The 
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fluorescence intensities of the cells were measured using the microplate reader 
(Genios, Tecan, Männedorf, Switzerland). The absorbance wavelength was set at 570 
nm and background wavelength at 660 nm. Cell viability was calculated in 
comparison with that of the control (consisting of the untreated cells). 
3.5  Animal Study 
 
The animal protocol was approved by the Institutional Animal Care and Use 
Committee (IACUC), National University of Singapore (#802/05(A10)09).  
Xenograft model was developed using SCID mice (female, 20 g). MCF-7 cancer cells 
were injected into the subcutaneous layer of the mice near the right flank at a 
concentration of 106 cells (100 µl). The tumors were allowed to develop to volumes 
of 150-200 mm3.  
 
3.5.1 Tumor imaging (MRI) 
 MRI was performed on the mice on a Bruker 7T Clinscan MRI system and was 
approved by the A*STAR Institutional Animal Care and Use Committee. Contrast 
agent was injected (dosage: 6.0 mg of Fe/kg body weight or equivalent of 1.5 mg of 
Cd/kg of body weight) through tail veins of the mice under 1% isoflurane anesthesia. 
T2-weighted images were acquired at various time points using T2-weighted turbo 
spin-echo sequence (TR/TE=1500/36 ms, resolution=100 µm, thickness=1 mm). 
MRIcro 1.40 (Chris Rorden ©1999-2005) was used to analyze the region of interest 
(ROI) of the MRI images. The images were color coded and the color was compared 
with that of the scale of signal intensity provided. Higher intensity was at regions of 




3.5.2 Tumor Imaging (Fluorescent Imaging) 
For fluorescent imaging study, the mice were sorted into 2 groups of 4. The mice in 
one group received a dose of the QDs and IO-loaded PLA-TPGS nanoparticles. Each 
20 g mouse was injected with the NPs formulation (dosage: 1.5 mg of Cd/kg of body 
weight or equivalent of 6.0 mg of Fe/kg body weight). The mice in the other group 
were left without any treatment to act as control. After 6 hours, perfusion procedures 
were conducted on all the mice to cleanse their organs of blood using PBS and fix 
them with formaldehyde. During perfusion, the anaesthetized mice had PBS 
introduced into them first via the left ventricles of their hearts to cleanse their organs. 
The superior and inferior vena cavae were snipped to release blood from the mice. 4% 
formalin was then introduced via the left ventricles to fix the organs. The organs were 
then harvested and used for fluorescent imaging. To monitor red fluorescence signals 
of QDs, ex vivo red fluorescence imaging of organs was acquired by IVIS imaging 
system (IVIS 100) coupled with cool CCD camera (Xenogen, Alameda, CA, USA). 
The detected light emitted from QDs was digitized and electronically displayed as a 
pseudo colour overlay onto a grayscale image of the organ. Images and measurements 
of fluorescence signals were acquired and analyzed with the Xenogen living imaging 
software v2.5 and quantified as photons per second.  The acquired signal intensities 









For biodistribution study, the mice were sorted into 2 groups of 4. The mice in one 
group received a dose of QDs and IOs-loaded PLA-TPGS nanoparticles. Each 20 g 
mouse was injected with the NPs formulation (dosage: 6.0 mg of Fe/kg body weight 
or equivalent of 1.5 mg of Cd/kg of body weight). The mice in the other group were 
left without any treatment to act as control. After 6 hours, perfusion procedures were 
conducted on all the mice to cleanse their organs of blood using PBS and fix them 
with formaldehyde. The mice were then sacrificed and their organs were collected, 
cryo-sectioned using a cryostat (LEICA CM3050S) and examined using the confocal 
laser-scanning microscope (CLSM, Olympus Fluoview FV1000, Japan).  
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CHAPTER 4: RESULTS & DISCUSSIONS 
 
 
4.1 Characterization of QDs and IOs-loaded nanoparticles 
 
 
4.1.1 Size and Size Distribution 
 
The size and size distribution of the QDs and IOs-loaded PLA-TPGS nanoparticles 
were measured by laser light scattering (LLS, 90-PLUS Analyzer, Brookhaven 
Instruments Corporation, USA) and are shown in Table 3.1. It can be observed that 
the diameters of the nanoparticles were around 325.8 nm with a PDI of 0.204. This 
shows that the particles were quite uniform in size and within the optimum cellular 
uptake range. 
 
4.1.2 Surface Charge 
The QDs and IOs-loaded PLA-TPGS nanoparticles were negatively charged at about -
37.3 mV as shown in Table 3.1. Zeta potential is an indicator of the stability of the 
nanoparticle suspension. A higher electric charge on the surface of the nanoparticles 
will prevent aggregation of the nanoparticles in buffer solution because of the strong 
repellent forces among particles (Mu L et al., 2002). Therefore, the nanoparticles 










Nanoparticle Size (nm) PDI ZP (mV) 





325.8 ± 5.2 0.204 ± 0.065 







Table 4.1: Characteristics of the QDs and IOs-loaded PLA-TPGS nanoparticles 
including particle size and polydispersity (PDI), zeta potential (ZP) and encapsulation 
efficiency percentage (EE%). 
 
4.1.3 TEM Analysis 
 
From the TEM image of QDs and IOs-loaded PLA-TPGS nanoparticles in Figure 
4.1C, well-formed nanoparticle with dark spots (QDs and IOs) encapsulated can be 
clearly seen. The QDs and IOs were encapsulated uniformly in the polymeric 
nanoparticle. As comparison, Figure 4.1A shows a TEM image of the IOs-loaded 
PLA-TPGS nanoparticles and Figure 4.1B shows that of the QDs-loaded PLA-TPGS 
nanoparticles. It can be observed that the QDs were actually elliptically shaped while 
the IOs were more spherically shaped. These TEM images show that the PLA-TPGS 
NPs were spherically shaped. 
 
Figure 4.1: TEM Images of  A: the IOs-loaded PLA-TPGS NPs, B: the QDs-loaded 
PLA-TPGS NPs and C: the QDs and IOs-loaded PLA-TPGS NPs (scale bar = 200 
nm). 
200 nm 200 nm 200 nm 
A B C 
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4.1.4 QDs and IO Encapsulation Efficiency  
 
It is difficult to differentiate the QDs from the IOs in the PLA-TPGS nanoparticles 
solely based on the TEM images. Hence, it is important to make use of the ICP-MS to 
measure the amount of Cd and Fe contents present in the PLA-TPGS nanoparticles to 
quantify the amount of the QDs and IO inside. The QDs and IOs encapsulation 
efficiencies in the PLA-TPGS nanoparticles are demonstrated in Table 4.1. The 
encapsulation efficiency of QDs is about 45% while that of IOs is about 60%. In 
general, the encapsulation efficiencies of QDs and IOs are relatively high. This may 
be due to the use of TPGS as the emulsifier at a relatively high concentration (15% by 
weight). TPGS is one of the most effective emulsifiers in the preparation of NPs. 
TPGS is a water-soluble derivative of natural vitamin E with a high hydrophile–
lipophile balance (HLB) of 13. Its bulky structure and large surface area make it an 
excellent emulsifier. High encapsulation efficiency suggests that less concentration of 
NPs will be needed to achieve a high concentration of the contrast agents for imaging. 
 
4.1.5 XPS 
X-ray photoelectron spectroscopy (XPS) can be applied to determine the elements or 
components present on the surface of a compound within a depth range of 1 to 10 nm. 
XPS can be used to test the types of elements present on the surface of the 
synthesized particles. QDs contain elements such as cadmium, selenium and zinc. 
XPS testing on the particle surfaces for these elements can indicate whether the QDs 
are actually encapsulated within the particles and not merely coated on the surfaces. 
The particles are also grinded to expose the contents within and sent for XPS testing 
again as a control to ascertain that QDs is present within the particles. Similarly, the 
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tests are repeated to test for iron to ascertain if IO (made up of iron) is present on the 
surface or inside the particles.   
Figure 4.2 shows XPS result indicating no cadmium (no peaks) on particle surfaces. 
When the particles are grinded (exposing the contents) and tested again using XPS, 
the result (Figure 4.3) shows 2 peaks at 401 eV and 408 eV binding energies, 








Figure 4.3: Grinded particle XPS for Cd showing 2 peaks (presence of Cd). 
 
 
Figure 4.4: Particle XPS result for Se showing no peaks (absence of Se). 
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Figure 4.5: Grinded particle XPS for Se showing 1 peak (presence of Se). 
 
 
Figure 4.6: Particle XPS result for Zn showing no peaks (absence of Zn). 
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Figure 4.7: Grinded particle XPS for Zn showing 2 peaks (presence of Zn). 
 
Figure 4.4 and 4.6 show XPS results also indicate no selenium and zinc on particle 
surfaces respectively. Thus, it can be concluded that there are no QDs found on the 
surface of the nanoparticles. Figure 4.5 shows a peak at 50 eV binding energy level 
indicating the presence of selenium within the particle. Figure 4.7 shows peaks at 
1019 eV and 1041 eV indicating the presence of zinc within the particle. This shows 
that the QDs detected using ICP-MS previously were indeed all from within the 
particles and not merely on the surfaces.  
Figure 4.8 shows XPS result indicating no iron present on the particle surfaces. Figure 
4.9 shows XPS result with 2 peaks at 709 eV and 723 eV binding energy levels 
indicating the presence of iron. This indicates that IO present in the nanoparticles is 
all encapsulated within the particles and not on the particle surfaces. Thus, it can be 
concluded that both QDs and IO are successfully encapsulated within the 
nanoparticles and not merely coated on the surfaces. 
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Figure 4.8: Particle XPS result for Fe showing no peaks (absence of Fe). 
 
 






4.2 Cell Line Experiment 
 
 
4.2.1 In vitro cellular uptake of NPs 
 
4.2.1.1 Qualitative study 
 
Figure 4.10 shows confocal laser scanning microscopy (CLSM) of MCF-7 cells after 
4 h treatment with the QDs and IO-loaded PLA-TPGS NPs at 37 °C, which were 
diluted to the NPs concentration with QDs equivalent to 1 µg Cd in 1 mL of media. 
The intensity coded (red for QDs and blue for DAPI) channels show the fluorescence. 
Figure 4.10B shows that the nuclei of the cells were effectively stained blue by DAPI. 
Figure 4.10C shows the cytoplasm of the cells emitting red coded fluorescence 
distinctive of QDs in the NPs, proving that the NPs have been successfully taken up 
































Figure 4.10: CLSM images of MCF-7 cells treated with the QDs and IOs-loaded 
PLA-TPGS NPs in vitro (scale bar = 10 µm). A: Bright field image of cells. B: Blue 







4.2.1.2 Quantitative study 
 
Figure 4.11 shows the respective fluorescence emission intensity of MCF-7 cells 
incubated for 1, 2 and 4 h in 100 µL of the QDs and IO-loaded PLA-TPGS NPs at the 
nanoparticle concentrations containing 1 µg/mL Cd, 0.5 µg/mL Cd and 0.25 µg/mL 
Cd respectively dispersed in medium. The readings were taken with a multiplate 
reader and the results were compared against the controls. The percentage uptake 
efficiency results of the cells treated with the NPs formulation at the various 
concentrations were calculated and displayed in Figure 4.11. From this graph, it is 
evident that the percentage uptake efficiency of the NPs formulation increases with 
increasing the nanoparticle concentrations. Furthermore, the percentage uptake 
efficiency was observed to be high at 40% - 50% within the first 4 h even at very low 
concentration. This shows that the PLA-TPGS NPs formulation of IOs and QDs 
indeed falls within suitable dimensions for cellular uptake. This also suggests that 
such a NPs formulation has great potential to passively deliver the contrast agents 






Figure 4.11: Cellular uptake efficiency of the MCF-7 cancer cells after 1, 2 and 4 h 
treatment with 100 µL of the QDs and IO-loaded PLA-TPGS NPs of concentrations 












4.2.2  In vitro Cytotoxicity  
 
QDs’ toxicity has posed to be a problem for their usage. Our results further confirm 
that IOs may also cause substantial toxicity, which was found in our earlier research 
(Wang Y et al., 2008). In fact, the cadmium present in the QDs, if released, could 
become seriously toxic to biological cells (Celik A et al., 2005). One practical 
solution for such toxicity problem of QDs and IOs used as probes for imaging is to 
apply nanoparticles of biodegradable polymers to encapsulate them as a shield from 
the cellular environment. The polymer chosen as the encapsulating medium in this 
research is PLA-TPGS, which may have better effects than any other biodegradable 
polymer or co-polymer.  PLA is FDA approved for clinical applications while TPGS 
is derived from naturally occurring vitamin E, i.e. a PEGylated Vitamin E. Thus, 
encapsulation of QDs and IOs in polymer matrix of PLA-TPGS reduces toxicity, 
enabling their usage for in vivo studies. In the in vitro cytotoxicity study, MCF-7 cells 
were treated with the synthesized QDs and IOs-loaded PLA-TPGS NPs, the free QDs 
and the free IOs (Resovist®) for a period of 24 h and 48 h respectively to make 
comparison of their cytotoxicity. The result of the cell viability expressed in 
percentage cell viability is shown in Fig 4.12. It can be seen from this graph that after 
24 h treatment, the viability of the cells treated with the QDs and IOs-loaded PLA-
TPGS nanoparticles at the designated nanoparticle concentrations was 95.4% in 
comparison with 81.3% for the same amount of QDs alone and 80.5% for the same 
amount of the IOs. Alternatively, the mortality of the cells treated with the QDs and 
IOs-loaded PLA-TPGS nanoparticles at the designated nanoparticle concentrations 
was 4.6% in comparison with 18.7% for the same amount of QDs alone and 19.5% 
for the same amount of the IOs. This shows that the free QDs and IO together may 
have about 8.3 times the cytotoxicity of the PLA-TPGS nanoparticles formulation 
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after 24-hour treatment. After 48 h treatment, the viability of the cells treated with the 
free QDs and IO were 78.1% and 78.5% (thus 21.9% and 21.5% mortality) 
respectively while that of the cells treated with the PLA-TPGS nanoparticle 
formulation of the same amount of QDs and IO was 92.0% (thus 8.0% mortality). 
This shows that the free QDs and IO together may have about 5.43 times the 














Figure 4.12: In vitro viability of MCF-7 cells after 24 and 48-hour treatment with the 
free IO, the free QDs (containing 1.42 µg/mL Cd), the free IO (containing 5.73 
µg/mL Fe), and the QDs and IOs-loaded PLA-TPGS NPs (containing 1.42 µg/mL Cd 







4.3 Animal Study 
 
 Multimodal probes formulated in biodegradable polymers provide excellent 
biocompatibility and stealth from the RES system. We show in this work a series of 
proof-of-concept experimental results for the PLA-TPGS nanoparticles formulation of 
QDs and IOs to realize a practical and effective way for multimodal imaging of 
cancer cells in vitro and tumor in vivo. Figure 4.13 shows MRI images obtained under 
T2 sequence of Xenograft model mice (20 g) injected with dual modal probe (6.0 mg 





Figure 4.13: Axial MRI image sections of the MCF-7 grafted tumor bearing mice. 
Images A and B show the part of the tumor (shown by the arrow) before and after 6 
hours of administration of the QDs and IOs-loaded PLA-TPGS NPs into the mice. 
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Images C and D show the kidney (K) and liver (L) part of the mice before and 6 hours 
after the administration of the PLA-TPGS NPs formulation of QDS and IOs (dosage: 
1.5 mg of Cd/kg of body weight or equivalent of 6.0 mg of Fe/kg body weight). The 
decrease in intensity in the regions of the tumor and liver can be noticed in 
comparison with the color scale shown aside.  
  
 The images were colour mapped using MRIcro (Chris Rorden © 1999-2005). IOs 
injected influence T2 and thus reduced the signal intensity at the site of accumulation. 
This can be seen in the MRI images in Figure 4.13, displaying a signal reduction in 
the regions of tumor, liver and kidney after 6 h. A signal reduction of 10% was 
observed in the tumor. In comparison, a greater percent of signal reduction of about 
50% was observed in the liver. In addition, signal reduction in the kidney was 
observed more at the medullar region of the kidney than at the cortical region. The 
results were similar to those reported by Prashant et al. (Prashant C et al., 2010).  
The uptake of the nanoparticles can be a result of passive targeting of the 
nanoparticles in the tumor due to its enhanced permeation and retention properties. 
However, there were not considerable differences in other parts of the viscera 
according to the MRI images. Though the images were acquired non-invasively with 
great anatomical resolution providing the possibility to view the animal body at great 
depths, these findings were actually restricted to a resolution of 1 µm (maximum that 
can be achieved by MRI).  
Figure 4.14 shows the fluorescent intensity ex vivo images of the various organs of the 
mice injected with the dual modal probes. Ex vivo images were acquired because the 
fluorescence of the respective organs obtained could be hindered due to the presence 
of skin, misrepresenting the actual intensities given out by the organs. The percentage 
 66 
fluorescent intensity increase in the organs is directly proportional to the amount of 
the nanoparticle accumulations. The PLA-TPGS NPs formulation was injected into 
mice at a dosage of 6.0 mg Fe/kg (equivalent of 1.5 mg Cd/kg). After 6 h, the mice 
were sacrificed; their organs were harvested for fluorescent imaging. Figure 4.14 
shows the result of the fluorescent imaging of the organs. The percentage increase in 
fluorescent intensities of the various organs were then calculated and plotted in Figure 





Figure 4.14: Fluorescent Images of the various organs. Upper row: control. Lower 
row: Organs of the mouse treated with the QDs and IOs-loaded PLA-TPGS NPs 







Figure 4.15: Fluorescence intensity increase percentage for the various organs of the 
mice treated with the QDs and IOs-loaded PLA-TPGS NPs (dosage: 1.5 mg of Cd/kg 
of body weight or equivalent of 6.0 mg of Fe/kg body weight). 
 
As the liver, kidneys and spleen act as major detoxifying organs, they are expected to 
contain high concentrations of NPs.  However, it is important to observe that there is 
about 153% increase in fluorescent intensity in the tumor. This shows that the tumor 
has passively uptaken a large amount of the NPs due to its poor drainage system. 
Hence, this exhibits how the PLA-TPGS NPs formulation could be used to detect and 
image tumors in vitro and in vivo. From Figure 4.15, it can be seen that fluorescent 
intensity percentage increase is 67% in the liver, 52% in the kidney and 153% in the 
tumor, which complements the finding from the MRI. The resolution of the 
fluorescence is greatly improved as shown in Figure 4.16, 4.17 and 4.18 (confocal). 
Figure 4.16D, 4.16E and 4.16F show the images of the liver section of a mouse 
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treated with the QDs and IOs-loaded PLA-TPGS NPs compared with a set of blank 

























Figure 4.16: Confocal laser scanning microscopy sections of the mouse liver (scale 
bar = 60 µm). Images A, B and C show the liver sections of the control with no 
treatment. A: Blue coded DAPI stained nuclei. B: Red channel detection showing no 
signal due to absence of QDs. C: Complete overlapped image of A and B. Images D, 
E and F show the liver sections of the mouse treated with the QDs and IOs loaded 
PLA-TPGS NPs. D: Blue coded DAPI stained nuclei. E: Red coded QD from NPs in 
cytoplasm. F: Complete overlapped image. 
 
Images 4.16A and 4.16D show the blue coded channels. Images 4.16B and 4.16E 
show the red coded channels. Images 4.16C and 4.16F had the red and blue coded 
channels overlapped. Both images of 4.16A and 4.16D registered blue signals, 
 69 
representing the nuclei of the liver cells stained blue by DAPI. Image 4.16B registered 
no red fluorescence indicating that QDs were absent. Image 4.16E however registered 
red fluorescence in the cytoplasm of the liver cells, indicating that QDs were present 
and suggesting that the NPs have been uptaken in the liver cells of the mouse. Similar 
findings were arrived at in the kidney sections (Figure 4.17) and the tumor sections 
(Figure 4.18). Therefore, in summary, the QDs and IOs-loaded PLA-TPGS NPs, 
when injected into the mice, were able to travel to and get internalized by the various 
















Figure 4.17: Confocal laser scanning microscopy sections of the mouse kidney 
sections (scale bar = 60 µm). Images A, B and C show the kidney sections of the 
control with no treatment. A: Blue coded DAPI stained nuclei. B: Red channel 
detection showing no signal due to absence of QDs. C: Complete overlapped image of 
A and B. Images D, E and F show the kidney sections of the mouse treated with the 
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QDs and IOs loaded PLA-TPGS NPs. D: Blue coded DAPI stained nuclei. E: Red 
















Figure 4.18: Confocal laser scanning microscopy sections of the mouse tumor 
sections. Images A, B and C (scale bar = 30 µm) show the tumor sections of the 
control with no treatment. A: Blue coded DAPI stained nuclei. B: Red channel 
detection showing no signal due to absence of QDs. C: Complete overlapped image of 
A and B. Images D, E and F (scale bar = 20 µm) show the tumor sections of the 
mouse treated with the QDs and IOs loaded PLA-TPGS NPs. D: Blue coded DAPI 
stained nuclei. E: Red coded QD from NPs in cytoplasm. F: Complete overlapped 
image. 
     
From these confocal images, it was clearly observed that the QDs and IOs-loaded 
PLA-TPGS NPs were internalized into the cytoplasmic regions of the various organ 
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cells. The findings of the MRI were thus confirmed by the confocal microscopy, 
wherein the medullar region of the kidney showed fluorescence and not the cortical 
region.  Thus it shows that the developed dual modal probe works. It has been 
exhibited that co-encapsulating both the QDs and IO contrast agents into a single 
polymeric nanoparticle probe has resulted in a probe that exhibits the advantages of 
both the individual contrast agents. This poses to be the key to limitless possibilities 
in terms of applications for human imagery.  Such a system of dual modality can be 
useful for pre- and during surgical treatment of cancer (Kircher MF et al., 2003; 
Mulder WJM et al., 2007). The non-invasive MRI imaging can ensure pre-operative 
identification of cancer while the less complicated fluorescent imaging techniques on 
operative procedure can ensure demarcation of tumor sites and delineation of healthy 
and normal cells. Moreover a method of molecular tracking can also be performed 
(Tada H, et al., 2007). MRI and fluorescence imaging on white mice induced with 
MCF-7 tumors injected with the nanoparticles were able to detect the locations of the 
tumors easily due to the passive targeting effect of the particles at the tumor sites, 
enhancing the contrast effect at the tumor locations. That suggested the possibility of 
using merely a single injection of the nanoparticles to utilize both MRI and 
fluorescence imaging for a patient to effectively detect any tumors within him. The 
results of both imaging modes can be cross-referenced to confirm the presence of a 
tumor at the same particular site imaged using both systems. In that way, early staged 
cancer not only would not be overlooked, but also could be more effectively detected 
and hence easily treated. Therefore, our results show the effectiveness of the designed 
dual modal probe in imaging tumors in the animal. Further refinements to this 
multimodal probe will realize its full potential in the imaging of the human body 
through various application possibilities.  
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CHAPTER 5: OUTLOOK 
 The work presented in this thesis describes a multimodal imaging approach by co-
encapsulating both IO and QDs to make use of both MRI and fluorescence imaging. 
This imaging system strikes at detecting cancer at its earliest stage where detection 
may be overlooked easily due to limitations with the use of only one imaging mode.  
This work can potentially be very useful for cancer imaging. However, it is still in its 
preliminay stage where some issues must first be addressed. 
The first and most crucial issue is the stability of the nanoparticles in the human body 
and their behavior within the human body until they are expelled from the body. The 
ideal scenario will definitely be that the particles do not break down to release the IO 
and QDs contained within. However, if the particles do break down to release the 
contrast agents before being expelled out of the body, the behaviors of the QDs 
should be investigated on until they were removed from the body. This is due to the 
toxicity of the QDs used. QDs commonly consist of cadmium and selenium in their 
core metalloid complexes. They will exhibit some toxic effects when they are broken 
down to their ionic forms. In general, the tricky situation is that not all QDs are alike. 
Therefore, it is impossible to categorize all engineered QDs into the same group of 
nanomaterials. QDs ADME and toxicity is based on various different factors derived 
from both inherent physicochemical properties and environmental conditions. These 
factors include QDs size, charge, concentration, outer coating bioactivity (capping 
material and functional groups), and oxidative, photolytic, and mechanical stability 
(Ron Hardman, 2006).  
Physicochemical property of a type of QDs affects its toxicity and each individual 
type of QDs possesses its own unique physicochemical properties. In general, there 
are discrepancies in the current available literatures regarding the toxicity of QDs. 
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This can be due to the lack of toxicology-based studies, the variety of QD 
dosage/exposure concentrations reported in the various available literatures, and the 
widely varying physicochemical properties of individual QDs. There are limited 
studies specifically designed for toxicological assessment of QDs. Hence, it is 
important to conduct a thorough toxicity assessment on the particular QDs used in this 
work to verify if it is suitable to be used as described in this thesis for human 
application. In the event, after toxicity assessment, that the particular QDs used in this 
work is not suitable, alternative types of QDs can be tested to find the most suitable 
QDs for the application described in this work. Furthermore, future optimization work 
can be done on parameters such as the concentrations and dosages of QDs to refine 
the imaging system. 
The second issue of this developed system is that it only has passive targeting effect 
in tumors. To enable even more enhanced detection of tumors, the surfaces of the 
synthesized IO and QDs encapsulated PLA-TPGS nanoparticles can be decorated 
with ligands that are specific to receptors found in abundance on the cancer tumors to 




CHAPTER 6: CONCLUSION 
I have developed an imaging system by co-encapsulation QDs and IOs in 
nanoparticles of PLA-TPGS copolymers for both MRI and fluorescent imaging.  
LLS, TEM, ICP-MS and XPS were used to characterize the developed particles. The 
size and size distribution of the nanoparticles (measured by laser light scattering) 
were around 325.8 nm in diameter with a PDI of 0.204. This shows that the particles 
were quite uniform in size and within the optimum cellular uptake range. They were 
negatively charged at about -37.3 mV suggesting that they were stable in solution. 
TEM images of QDs and IOs-loaded PLA-TPGS nanoparticles showed spherical 
well-formed nanoparticle with dark spots (QDs and IOs) encapsulated uniformly in 
the polymeric nanoparticle. QDs were elliptically shaped while the IOs were 
spherically shaped.  
ICP-MS was used to measure the amount of Cd and Fe contents present in the 
nanoparticles to quantify the amount of the QDs and IO inside. The encapsulation 
efficiency of QDs was found to be about 45% while that of IOs was about 60%. The 
encapsulation efficiencies of QDs and IOs were relatively high. High encapsulation 
efficiency suggests that less concentration of NPs will be needed to achieve a high 
concentration of the contrast agents for imaging. 
XPS was used to test the types of elements present on the surface of the synthesized 
particles. QDs contain elements such as cadmium, selenium and zinc while IO 
contains iron. XPS testing on the particle surfaces for these elements can indicate 
whether the QDs and IO were actually encapsulated within the particles and not 
merely coated on the surfaces. The particles were also grinded to expose the contents 
within and sent for XPS testing again as a control. XPS results revealed that 
cadmium, selenium, zinc and iron were only detected within and not on the surfaces 
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of the particles. That concluded successful encapsulation of QDs and IO within the 
nanoparticles. 
In Vitro tests were then conducted to find out the cellular uptake of the particles in 
MCF-7 breast cancer cells. Cytotoxicity tests were also conducted on the cells to find 
out the toxicity of the particles. For the qualitative in vitro cell uptake study, MCF-7 
cells were treated with the QDs and IO-loaded PLA-TPGS NPs at 37 °C for 4 h. The 
NPs concentration used was the QDs equivalent to 1 µg Cd in 1 mL of media. 
Confocal laser scanning microscopy on the treated cells showed red coded 
fluorescence distinctive of QDs in the NPs in the cytoplasm of the cells, proving that 
the NPs have been successfully taken up into the cells. For the quantitative cell uptake 
study, MCF-7 cells were incubated for 1, 2 and 4 h in 100 µL of the QDs and IO-
loaded PLA-TPGS NPs at the nanoparticle concentrations containing 1 µg/mL Cd, 
0.5 µg/mL Cd and 0.25 µg/mL Cd respectively dispersed in medium. The readings 
were taken with a multiplate reader and the results were compared against the 
controls. The percentage uptake efficiency results of the cells treated with the NPs 
formulation at the various concentrations were calculated and charted in a graph. The 
results showed that the percentage uptake efficiency of the NPs formulation increases 
with increasing nanoparticle concentrations. The percentage uptake efficiency was 
observed to be high at 40 - 50% within the first 4 h even at very low concentration 
showing that the formulated NPs indeed falls within suitable dimensions for cellular 
uptake. 
In the in vitro cytotoxicity study, MCF-7 cells were treated with the synthesized QDs 
and IOs-loaded PLA-TPGS NPs, the free QDs and the free IOs (Resovist®) for a 
period of 24 and 48 h respectively to make comparison of their cytotoxicity. The 
results showed that after 24 h treatment, the viability of the cells treated with the QDs 
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and IOs-loaded PLA-TPGS nanoparticles at the designated nanoparticle 
concentrations was 95.4% in comparison with 81.3% for the same amount of QDs 
alone and 80.5% for the same amount of the IOs. Alternatively, the mortality of the 
cells treated with the QDs and IOs-loaded PLA-TPGS nanoparticles at the designated 
nanoparticle concentrations was 4.6% in comparison with 18.7% for the same amount 
of QDs alone and 19.5% for the same amount of the IOs. This shows that the free 
QDs and IO together may have about 8.3 times the cytotoxicity of the PLA-TPGS 
nanoparticles formulation after 24-hour treatment. After 48 h treatment, the viability 
of the cells treated with the free QDs and IO were 78.1% and 78.5% (thus 21.9% and 
21.5% mortality) respectively while that of the cells treated with the PLA-TPGS 
nanoparticle formulation of the same amount of QDs and IO was 92.0% (thus 8.0% 
mortality). This shows that the free QDs and IO together may have about 5.43 times 
the cytotoxicity of the PLA-TPGS nanoparticles formulation after 48-hour treatment. 
Multimodal probes formulated in biodegradable polymers provide excellent 
biocompatibility and stealth from the RES system. A series of proof-of-concept 
experiments was conducted on white mice with the formulated particles to show that 
multimodal imaging of cancer cells in vitro and tumor in vivo is practical and 
effective. MRI images were taken under T2 sequence of Xenograft model mice (20 g 
mice with induced MCF-7 cancer tumor) injected with dual modal probe (6.0 mg 
Fe/kg and 1.5 mg Cd/kg). IOs injected influence T2 and thus reduced the signal 
intensity at the site of accumulation. That can be seen in the MRI images displaying a 
signal reduction in the regions of tumor, liver and kidney after 6 h. A signal reduction 
of 10% was observed in the tumor. In comparison, a greater percent of signal 
reduction of about 50% was observed in the liver. In addition, signal reduction in the 
kidney was observed more at the medullar region of the kidney than at the cortical 
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region. The uptake of the nanoparticles can be a result of passive targeting of the 
nanoparticles in the tumor due to its enhanced permeation and retention properties. 
The mice used were then harvested of their organs, which were then sent for 
fluorescence imaging. Ex vivo images were acquired because the fluorescence of the 
respective organs obtained could be hindered due to the presence of skin, 
misrepresenting the actual intensities given out by the organs. The percentage 
fluorescent intensity increase in the organs is directly proportional to the amount of 
the nanoparticle accumulations. The percentage increase in fluorescent intensities of 
the various organs were then calculated and plotted in a graph to investigate the 
biodistribution of the NPs after being injected into the mice. 
As the liver, kidneys and spleen act as major detoxifying organs, they were expected 
to contain high concentrations of NPs.  There was about 153% increase in fluorescent 
intensity in the tumor. That suggested that the tumor has passively uptaken a large 
amount of the NPs due to its poor drainage system. That exhibited how the PLA-
TPGS NPs formulation could be used to detect and image tumors in vitro and the 
tumor itself in vivo. It was observed that fluorescent intensity percentage increase is 
67% in the liver, 52% in the kidney and 153% in the tumor, which complements the 
finding from the MRI. Confocal imaging of the tumor, liver and kidney sections 
showed QDs fluorescence from the sections, further confirming that the QDs and IOs-
loaded PLA-TPGS NPs, when injected into the mice, were able to travel to and get 
internalized by the various organ cells as well as by the tumor cells.  
The experimental results showed that the developed IO and QDs loaded PLA-TPGS 
nanoparticles can be effectively uptaken into cancer cells in vitro. In vivo studies on 
white mice also revealed that the particles could be uptaken passively into the tumor.  
The PLA-TPGS coating has shielded the contrast agents (IO and QDs), which were 
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encapsulated within from detection by the human immune system. Thus, increasing 
their half-life in circulation and realizing sustained and controlled delivery of imaging 
agents with passive targeting effects for the tumors. Such a multimodal imaging 
system marries the advantages of both contrast agents making the resultant probe 
highly sensitive with good depth penetration. This union of QDs and IO as a single 
probe strives to improve imaging with practical clinical feasibility.  
MRI and fluorescence imaging on white mice induced with MCF-7 tumors injected 
with the nanoparticles were able to detect the locations of the tumors easily due to the 
passive targeting effect of the particles at the tumor sites, enhancing the contrast 
effect at the tumor locations. That suggested the possibility of merely a single 
injection of the nanoparticles to utilize both MRI and fluorescence imaging for a 
patient to effectively detect any tumors within him. The results of both imaging 
modals can be cross-referenced to confirm the presence of a tumor at the same 
particular site imaged using both systems. In that way, early staged cancer could be 
more effectively detected and easily treated. 
The in vitro cell toxicity tests revealed that the formulated nanoparticles were 
significantly less toxic than the respective individual contrast agents. Free QDs and 
IO together have about 8.3 times and 5.43 times the cytotoxicity of the PLA-TPGS 
nanoparticles formulation after 24-hour and 48-hour treatments respectively. 
Furthermore, animal testing showed that the polymeric coating was able to protect the 
contrast agents from human immune system detection until they travel to the intended 
imagery sites. Hence showing that the coating was stable and could increase 
circulation time of the probe. However, the stability of the nanoparticles within the 
human body was not studied and thus further work can be done to investigate the 
stability of the nanoparticles under human body conditions. On the other hand, studies 
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should also be done on the stability of the IO and QDs encapsulated within the 
nanoparticles in event that the nanoparticles break down within the human body 
before being removed from the body. The stability of the contrast agents, especially 
the QDs, could determine the visibility of the system to be applied to human. If the 
QDs were to break down into toxic ionic forms before being expelled out of the 
human body, alternative QDs should be explored to find the most suitable QDs for 
this system. 
MRI and fluorescent imaging have both confirmed the ability of such a nanoparticle 
formulation system to passively target tumor in mice. I envision further development 
of this technology, particularly by incorporating drugs into the nanoparticles and 
surface modifying the nanoparticle surfaces with targeting ligands to target 
corresponding kinds of cancers. This will open exciting opportunities in traceable 
delivery and also improve imaging to the extent that cancers can be accurately 
detected even at very early stages, enabling cancers to be cured before they develop 
into terminal stages. 
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